Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome (ShIP)
Primary Purpose
Shoulder Impingement Syndrome
Status
Terminated
Phase
Not Applicable
Locations
Lebanon
Study Type
Interventional
Intervention
platelet-rich plasma group
Methylprednisolone group
Sponsored by
About this trial
This is an interventional treatment trial for Shoulder Impingement Syndrome focused on measuring Subacromial injection, methylprednisolone, treatment, Platelet-rich plasma
Eligibility Criteria
Inclusion Criteria:
- Any adult male or female between 18 and 65 years of age, inclusive, with clinical diagnosis of shoulder subacromial impingement
Exclusion Criteria:
- Age below 18 or above 65 years
- History of prior shoulder injections or surgery
- History of fracture of the acromion, clavicle, scapula, or proximal humerus
- Known allergy to corticosteroids
- Known allergy to lidocaine
Sites / Locations
- American University of Beirut Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
platelet-rich plasma group
Methylprednisolone group
Arm Description
Autologous platelet-rich plasma subacromial injection
Methylprednisolone subacromial injection
Outcomes
Primary Outcome Measures
Constant-Murley Total Score
The sum of scores from different domains of Constant-Murley Questionnaire
Secondary Outcome Measures
Constant-Murley Pain Score
Pain score derived from Pain domain of Constant-Murley Questionnaire
Constant-Murley Function score
Function score derived from function domain of Constant-Murley Questionnaire
Constant-Murley ROM score
Range of motion assessment score derived from range of motion domain of Constant-Murley Questionnaire
Full Information
NCT ID
NCT02669303
First Posted
October 15, 2015
Last Updated
June 27, 2017
Sponsor
American University of Beirut Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02669303
Brief Title
Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome
Acronym
ShIP
Official Title
Comparing Subacromial Injection of Platelet-rich Plasma Versus Methylprednisolone in the Treatment of Shoulder Subacromial Impingement Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Terminated
Why Stopped
low recruitment rate and high rate of loss-to-followup
Study Start Date
September 2015 (undefined)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
American University of Beirut Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether injection of platelet-rich plasma derived from patient's blood is effective in treatment of shoulder subacromial impingement syndrome as compared to the current protocol of methylprednisolone injection.
Detailed Description
Patients presenting with shoulder pain to the study location will be screened by the principal investigator. Once diagnosed clinically with shoulder subacromial impingement syndrome, they will be invited to join the study. They will be invited to separate academic office to be explained about the study, its voluntary and confidential basis as per our Institutional Review Board (IRB) approved protocols.
After signing informed consent form and recruitment, they will be assigned randomly to one of the study arms through software-generated sequential allocation packaged in an opaque envelope. All involved except the principal investigator and patient are blinded.
There are two groups/arms in the study. The experimental arm will include subacromial injection of study subjects with autologous platelet-rich plasma; wheres subjects in the other study arm will be injected with methylprednisolone.
The outcome will be assessed through three scores. The study subjects will be asked to complete Oxford Shoulder Score questionnaire and health-related quality of life SF-36 questionnaire and Constant-Murley score will be measured through physician-based assessment done by the residents involved in the study. This will be done during the baseline visit before injection and repeated at 2, 6, 12 weeks and 6 months follow-up visits.
Also any adverse effects of both treatment arms will be monitored and reported as appropriate.
The investigators hypothesize that injecting platelet-rich plasma into the subacromial space of patients with subacromial impingement will result in decreased pain and increased function at 6 months follow-up (assessed by Constant-Murley Score, Oxford Shoulder Score, and Short Form-36 (SF-36) questionnaire) as compared to patients injected with methylprednisolone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shoulder Impingement Syndrome
Keywords
Subacromial injection, methylprednisolone, treatment, Platelet-rich plasma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
platelet-rich plasma group
Arm Type
Experimental
Arm Description
Autologous platelet-rich plasma subacromial injection
Arm Title
Methylprednisolone group
Arm Type
Active Comparator
Arm Description
Methylprednisolone subacromial injection
Intervention Type
Drug
Intervention Name(s)
platelet-rich plasma group
Other Intervention Name(s)
autologous platelet-rich plasma, PRP
Intervention Description
Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the "Recover(TM) Platelet Separation Kit" (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder.
Intervention Type
Drug
Intervention Name(s)
Methylprednisolone group
Other Intervention Name(s)
methylprednisolone acetate
Intervention Description
Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
Primary Outcome Measure Information:
Title
Constant-Murley Total Score
Description
The sum of scores from different domains of Constant-Murley Questionnaire
Time Frame
6 months post-injection
Secondary Outcome Measure Information:
Title
Constant-Murley Pain Score
Description
Pain score derived from Pain domain of Constant-Murley Questionnaire
Time Frame
6 months post-injection
Title
Constant-Murley Function score
Description
Function score derived from function domain of Constant-Murley Questionnaire
Time Frame
6 months post-injection
Title
Constant-Murley ROM score
Description
Range of motion assessment score derived from range of motion domain of Constant-Murley Questionnaire
Time Frame
6 months post-injection
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Any adult male or female between 18 and 65 years of age, inclusive, with clinical diagnosis of shoulder subacromial impingement
Exclusion Criteria:
Age below 18 or above 65 years
History of prior shoulder injections or surgery
History of fracture of the acromion, clavicle, scapula, or proximal humerus
Known allergy to corticosteroids
Known allergy to lidocaine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muhyeddine Al-Taki, MD
Organizational Affiliation
American University of Beirut Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
American University of Beirut Medical Center
City
Beirut
ZIP/Postal Code
11-236
Country
Lebanon
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21422467
Citation
Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med. 2011 Jun;39(6):1200-8. doi: 10.1177/0363546510397173. Epub 2011 Mar 21.
Results Reference
background
PubMed Identifier
15779147
Citation
Anitua E, Andia I, Sanchez M, Azofra J, del Mar Zalduendo M, de la Fuente M, Nurden P, Nurden AT. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005 Mar;23(2):281-6. doi: 10.1016/j.orthres.2004.08.015.
Results Reference
background
PubMed Identifier
20044683
Citation
Karthikeyan S, Kwong HT, Upadhyay PK, Parsons N, Drew SJ, Griffin D. A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement. J Bone Joint Surg Br. 2010 Jan;92(1):77-82. doi: 10.1302/0301-620X.92B1.22137.
Results Reference
background
Learn more about this trial
Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome
We'll reach out to this number within 24 hrs